This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
12/2/2020
Good day, everyone, and welcome to the New Frontier Health Corporation Third Quarter 2020 Earnings Conference Call. Please note that today's call is being recorded. I would now like to turn the conference over to Mr. Bill Zima of ICR. Please go ahead.
Thank you, Operator. Hello, everyone, and welcome to New Frontier Health Third Quarter 2020 Earnings Conference Call. The company's earnings results were released earlier today and are available on the company's IR website at www.newfrontierhealth.com. In addition, remarks today will be accompanied by a presentation, which can also be found on the company's IR website. Before we continue, please note that the discussion today will contain forward-looking statements made under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve inherent risks and uncertainties. As such, our results may be materially different from the views expressed today. Further information regarding these and other risks and uncertainties is included in our Form 20F, filed with the U.S. Securities and Exchange Commission on March 31, 2020, and other documents filed with the U.S. SEC. New Frontier does not assume any obligation to update any forward-looking statements, except as required under applicable law. This press release also includes financial measures that are not calculated in accordance with international financial reporting standards, as issued by the International Accounting Standard Board. For reconciliation of these measures to most comparable measures calculated in accordance with IFRS, please see the earnings release or investor presentation published by New Frontier Health today and file with the SEC on Form 6-K. Allow me to introduce the management team on the call today. Ms. Roberta Lifson, Chief Executive Officer of New Frontier Health, and Mr. Carl Wu, President of NFH and Chairman of the Executive Committee of the Board, will provide updates for the quarter. Following managed prepared remarks, we will open up the call to questions. During the Q&A session, Mr. Walter Hsu, CFO of NFH, and Mr. David Zung, COO of NFH, will also be available to answer any questions. With that said, I would now like to turn the call over to Roberta. Roberta, please go ahead.
Thank you, Bill, and hello, everyone. Thank you for joining us for a discussion of our third quarter 2020 results. During this quarter, as the pandemic continued to evolve around the world, we were pleased with the performance of each of our business segments. Both the macro economy and patient behavior gradually returned to near normal this quarter, driving sequential growth in our revenues and patient volumes. We are optimistic about the ongoing trend in our recovery observed in the quarter as demonstrated by the increase in both outpatient and inpatient numbers from the prior quarter. For those of you following along with our presentation deck, please turn to slide 14 for a snapshot of the quarter. As the Chinese government implemented various measures during the pandemic, the COVID situation has begun substantially to come under control, and the economy started to pick up across the country towards the end of Q2 and throughout Q3. We have also seen a significant recovery in our business this quarter, as patient visits increased significantly from Q2 by 21.7%, Late July saw a spike in cases here in China and a temporary reinstitution of emergency control. After the resulting restrictions were eased in August, outpatient volumes began to recover significantly. By September, total outpatient volume of operating assets had exceeded the volume of the same month last year. We have seen similar recovery trends for inpatient admissions, which increased by 7.3% in Q3 2020 over Q2. Most of the increased admissions were for major surgery and medical cases. However, total inpatient admissions were still 15.1% lower than last year's level, primarily due to few admissions in the obstetrics department as a result of a continued decrease in the birth rate across China and fewer admissions in pediatrics as well as schools remain closed and enhanced personal hygiene and protective measures for school children were implemented. In addition, both outpatient and inpatient ASP increased this quarter as a result of an increase in the number of higher acuity services offered at our facilities. As a result, our revenue in Q3 2020 recorded a 3.7% year-over-year increase and a 14.1% increase from the prior quarter. We were also pleased to continue to achieve strong growth in adjusted EBITDA in the third quarter. Adjusted EBITDA increased by 162.8% year-over-year. The increase in revenue in Yubadana were primarily attributable to the steady recovery of patient volumes in various specialties across our facilities and the implementation of cost savings initiatives, as well as strong ramp-up of our expansion assets in Guangzhou and Shanghai Pudong, which achieved 36% year-on-year growth in revenue in Q3 2020. Please now turn to slide 15, which illustrates the recovery of both our local and expat patient bases. Due to the closure of international borders and other travel restrictions within China since the pandemic's onset, the company has seen a shift in patient mix. there was significantly higher volume and revenue contributions from domestic patients across the USH network. Despite a temporary re-imposition of restrictions in Beijing, the company recorded 11% year-over-year growth in revenue from local patients in Q3. In September, revenue from Chinese patients reached 16% year-over-year growth. This demonstrates high resilience and an increase in demand for premium private healthcare services from Chinese consumers. However, although foreign patient buy-in during the third quarter still lags pre-pandemic periods, we continue to see a favorable trend in recovery. And in fact, there was an increase in foreign patient buy-in in the third quarter compared to the second quarter. On September 28th, the Chinese government announced a slight easing of the travel restrictions of foreign nationals coming into China. And as a result, we expect to see continued recovery of foreign patient volumes. We are pleased with our latest recovery and believe it bodes well for the growth of our business. I'll now turn the call over to Carl Wu, who will share our latest developments from recent months. Carl, please go ahead.
You're reading a preview of the NFH Q3 2020 earnings call.
Free account.
